Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mendell

Showing results (471-480 of 889) with videos related to

Pageof 89
Sort By:
Neurology|January 25, 2006
Pilot trial of etanercept in the treatment of inclusion-body myositisR J Barohn, L Herbelin, J T Kissel, et al.
Annals of Neurology|June 1, 1996
Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY GroupR Tawil, J Forrester, R C Griggs, et al.
Journal of Neuropathology and Experimental Neurology|April 16, 2026
The NORAD-Pumilio regulatory axis in the evolution of inclusion body myositisLingying Tong, Burcak Ozes, Kyle Moss, et al.
IEEE Transactions on Rehabilitation Engineering : a Publication of the IEEE Engineering in Medicine and Biology Society|December 1, 1996
Therapeutic neural effects of electrical stimulationJ J Daly, E B Marsolais, L M Mendell, et al.
Muscle & Nerve|July 23, 2009
Utility of cystatin C to monitor renal function in Duchenne muscular dystrophyLaurence Viollet, Susan Gailey, David J Thornton, et al.
Neuroscience Letters|May 22, 2012
Gene therapy for muscular dystrophy: lessons learned and path forwardJerry R Mendell, Louise Rodino-Klapac, Zarife Sahenk, et al.
Human Gene Therapy|June 17, 2015
Human α7 Integrin Gene (ITGA7) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient MiceKristin N Heller, Chrystal L Montgomery, Kimberly M Shontz, et al.
BMC Proceedings|March 1, 2012
Principal components ancestry adjustment for Genetic Analysis Workshop 17 dataJing Jin, Jane E Cerise, Sun Jung Kang, et al.
Neuromuscular Disorders : NMD|December 18, 2013
The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositisL N Alfano, L P Lowes, I Dvorchik, et al.
Neurology|October 24, 2001
Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophyJ T Kissel, M P McDermott, J R Mendell, et al.
Pageof 89

Showing results (471-480 of 889) with videos related to

Sort By:
Pageof 89
Neurology|January 25, 2006
Pilot trial of etanercept in the treatment of inclusion-body myositisR J Barohn, L Herbelin, J T Kissel, et al.
Annals of Neurology|June 1, 1996
Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY GroupR Tawil, J Forrester, R C Griggs, et al.
Journal of Neuropathology and Experimental Neurology|April 16, 2026
The NORAD-Pumilio regulatory axis in the evolution of inclusion body myositisLingying Tong, Burcak Ozes, Kyle Moss, et al.
IEEE Transactions on Rehabilitation Engineering : a Publication of the IEEE Engineering in Medicine and Biology Society|December 1, 1996
Therapeutic neural effects of electrical stimulationJ J Daly, E B Marsolais, L M Mendell, et al.
Muscle & Nerve|July 23, 2009
Utility of cystatin C to monitor renal function in Duchenne muscular dystrophyLaurence Viollet, Susan Gailey, David J Thornton, et al.
Neuroscience Letters|May 22, 2012
Gene therapy for muscular dystrophy: lessons learned and path forwardJerry R Mendell, Louise Rodino-Klapac, Zarife Sahenk, et al.
Human Gene Therapy|June 17, 2015
Human α7 Integrin Gene (ITGA7) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient MiceKristin N Heller, Chrystal L Montgomery, Kimberly M Shontz, et al.
BMC Proceedings|March 1, 2012
Principal components ancestry adjustment for Genetic Analysis Workshop 17 dataJing Jin, Jane E Cerise, Sun Jung Kang, et al.
Neuromuscular Disorders : NMD|December 18, 2013
The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositisL N Alfano, L P Lowes, I Dvorchik, et al.
Neurology|October 24, 2001
Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophyJ T Kissel, M P McDermott, J R Mendell, et al.
Pageof 89